At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MGRX Mangoceuticals, Inc.
Not Yet Opened 03-27 16:00:00 EDT
2.38
-0.09
-3.64%
盘后2.29
-0.09-3.86%
19:48 EDT
| High2.49 | Low2.27 | Vol142.58K |
| Open2.33 | D1 Closing2.47 | Amplitude8.91% |
| Mkt Cap12.30M | Tradable Cap8.66M | Total Shares5.17M |
| T/O335.04K | T/O Rate3.92% | Tradable Shares3.64M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Mangoceuticals Inc - Secures Exclusive Rights for Diabetinol in U.S. and Canada
THOMSON REUTERS · 03-25 13:10
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
GlobeNewswire · 03-25 13:00
Mangoceuticals, Inc. Approves Key Amendments at Special Meeting
TIPRANKS · 03-19
BRIEF-Mangoceuticals Announces The Launch Of “Peachesrx”
Reuters · 02-20
Mangoceuticals Announces the Launch of “Peachesrx” - a Women's Telehealth Brand Focused on Personalized Wellness and Glp-1 Weight Loss Treatments
THOMSON REUTERS · 02-20
BRIEF-Mangoceuticals Advances Research On Avian Flu Solution For Poultry
Reuters · 02-12
Mangoceuticals Inc - Advances Research on Avian Flu Solution for Poultry
THOMSON REUTERS · 02-12
Mangoceuticals Inc - Engages Vipragen Biosciences for Antiviral Studies
THOMSON REUTERS · 02-12
Mangoceuticals Inc - Initial H1n1 Trial Shows Significant Reduction in Viral Load
THOMSON REUTERS · 02-06
Mangoceuticals Advances H1n1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5n1 Cohort for Expanded Research
THOMSON REUTERS · 02-06
Mangoceuticals executes exclusive distribution agreement with Propre
TIPRANKS · 02-03
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement With Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
THOMSON REUTERS · 02-03
Mangoceuticals, Inc. Finalizes Debt Conversion and Appointments
TIPRANKS · 01-21
BUZZ-Hims & Hers shines bright in a testing year for telehealth stocks
Reuters · 2024-12-31
Mangoceuticals Shares Rise 22%, Company Acquires Mushroom-Based Wellness and Innovations Patent
Dow Jones · 2024-12-19
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
THOMSON REUTERS · 2024-12-19
Mangoceuticals initiates investigation into potential stock manipulation
TIPRANKS · 2024-12-04
Mangoceuticals, Inc. Initiates Investigation Into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
THOMSON REUTERS · 2024-12-04
Mangoceuticals, Inc. Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
THOMSON REUTERS · 2024-10-31
Mangoceuticals Shares Fall 3.3% on Plan to Evaluate Potential Strategic Alternatives
THOMSON REUTERS · 2024-10-22
Introduction
Company Name.
Mangoceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App